Business Wire

MN-DIGI-INTERNATIONAL

Share
Digi International Launches Digi Containers to Improve Development, Operation, and Management of Custom Applications on Digi Cellular Routers

Digi International, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched Digi Containers, a software service that enables the development and operation of custom applications on Digi cellular routers that run DAL OS. Digi Containers leverage the Digi Remote Manager® platform as the central portal for deploying and managing these applications.

The Digi Containers service helps developers take the fullest advantage of edge computing by providing the flexibility to deploy new services and apps while consolidating edge-processing hubs. These edge applications offer low latency and near-real-time responsiveness with the agility to respond to evolving use cases.

Through Digi Containers, developers employ Lightweight Linux Containers (LXCs) — essentially virtual machines (VMs) that share the physical device’s running kernel. This enables processes inside a container to run at native speed as if they are actually running directly on the host device. Since containers are lightweight and portable, they offer both security and flexibility. This enables developers to expand on the capabilities of Digi solutions to support specific needs.

As a value-added service for Digi cellular routers, Digi Containers enable users to upload, manage, deploy, and monitor container-based applications through Digi Remote Manager. This empowers companies to orchestrate and manage a complex series of containers in various structures and configurations. Digi Containers provide:

  • Portability – A containerized application can be deployed in private and public clouds. Companies gain flexibility because they can easily move workloads among environments and providers.
  • Scalability – Containers can scale horizontally (i.e., you can “clone” identical containers within the same cluster to expand capacity/throughput as needed). By running only what is needed, when needed, costs decrease significantly.
  • Increased security – By design, containers are inherently isolated. If one container is compromised, others won’t be affected.
  • Speed – Autonomy from the operating system gives greater control. You can start/stop a container in seconds. You achieve faster development and operational speed and a faster and smoother user experience.
  • Efficiency – Since a separate operating system isn’t required, containers require fewer resources than VMs. You can run several containers on a single server. Less hardware means lower costs and fewer points of failure.

“The launch of Digi Containers unlocks the power of edge computing on Digi cellular routers,” said Kinana Hussain, Vice President of Product Management. “By building in the embedded software environment on our devices, along with their inherent computational capabilities, developers can tap into a rich and growing set of features, capabilities, and services. These are all signed, vetted, and distributed as part of the Digi TrustFence® security framework to more easily create and support a variety of demanding containerized applications in the enterprise, industrial, and transportation markets.”

Digi Enhances Network Analytics Application

Recently, Digi also upgraded Digi intelliFlow® in Digi Remote Manager, further strengthening Digi’s edge-to-cloud software stack. Digi intelliFlow provides a graphical visualization of network application data, focusing on the top 10 users or top 10 destinations. This intuitive representation of network activity allows organizations to update settings on Digi routers or tailor the network to the site’s needs. Digi intelliFlow provides recent data and a historical reference to keep networks running smoothly. intelliFlow addresses excessive data usage with custom alarms that alert administrators when data limits are approaching.

“Our long-term vision is to enable a full suite of market vertical-specific value-added services that leverage our robust edge-to-cloud software stack to help our customers maximize their IoT investments while focusing on their core business,” said Hussain.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye